At the time of writing, Blueprint Medicines Corp [BPMC] stock is trading at $114.91, down -0.62%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BPMC shares have gain 10.54% over the last week, with a monthly amount glided 27.48%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Blueprint Medicines Corp [NASDAQ: BPMC] stock has seen the most recent analyst activity on November 14, 2024, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $126. Previously, UBS started tracking the stock with Neutral rating on October 24, 2024, and set its price target to $88. On May 14, 2024, Stephens initiated with a Overweight rating and assigned a price target of $140 on the stock. Leerink Partners upgraded its rating to a Market Perform and increased its price target to $97 on May 06, 2024. Oppenheimer upgraded its rating to a Outperform but $85 remained the price target by the analyst firm on October 27, 2023. Needham reiterated a Buy rating for this stock on August 21, 2023, and upped its price target to $66. In a note dated July 31, 2023, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $55 to $82.
For the past year, the stock price of Blueprint Medicines Corp fluctuated between $72.24 and $121.90. Currently, Wall Street analysts expect the stock to reach $122.6 within the next 12 months. Blueprint Medicines Corp [NASDAQ: BPMC] shares were valued at $114.91 at the most recent close of the market. An investor can expect a potential return of 6.69% based on the average BPMC price forecast.
Analyzing the BPMC fundamentals
According to Blueprint Medicines Corp [NASDAQ:BPMC], the company’s sales were 434.41M for trailing twelve months, which represents an 126.61% jump. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -0.64%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.48 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.51.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 113.87 points at the first support level, and at 112.84 for the second support level. However, for the 1st resistance point, the stock is sitting at 116.71, and for the 2nd resistance point, it is at 118.52.
Ratios To Look Out For
It is important to note that Blueprint Medicines Corp [NASDAQ:BPMC] has a current ratio of 3.32. In addition, the Quick Ratio stands at 3.27 and the Cash Ratio stands at 0.35. Considering the valuation of this stock, the price to sales ratio is 16.80, the price to book ratio is 23.28.
Transactions by insiders
Recent insider trading involved Haviland Kate, CHIEF EXECUTIVE OFFICER, that happened on Jan 21 ’25 when 1446.0 shares were sold. CHIEF OPERATING OFFICER, Rossi Christina completed a deal on Jan 21 ’25 to sell 2274.0 shares. Meanwhile, Director Albers Jeffrey W. sold 15161.0 shares on Jan 21 ’25.
